Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > New N43-101 is on the way
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by waynedon Oct 13, 2010 4:22pm
218 Views
Post# 17560520

RE: RE: New N43-101 is on the way

RE: RE: New N43-101 is on the way   If you check the base metal charts at Kitco you will see that in the last several months the stockpiles of zinc and copper have tanked . So the price of both has strength for some time to come on real demand. The same with gold and silver . The spike is being caused by demand not on the U.S. $ .
   We need real news here besides financings and insider options and we need it soon or people put their money elsewhere . When its put elsewhere it doesn`t come back.
  As for yesterday`s price , it was most likely someone selling at market who didn`t know what would happen . Shows you though how poor the support was . We need to get by that for this turkey to become an eagle and start to soar .
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities